Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Jean‐Claude Tardif, Nadia Bouabdallaoui, Philippe L. L’Allier, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 8, pp. 924-932
Open Access | Times Cited: 258

Showing 1-25 of 258 citing articles:

Cytokine Storm in COVID-19: Immunopathogenesis and Therapy
Christian Zanza, Tatsiana Romenskaya, A Manetti, et al.
Medicina (2022) Vol. 58, Iss. 2, pp. 144-144
Open Access | Times Cited: 240
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 12, pp. 1419-1426
Open Access | Times Cited: 171
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1059-1103
Open Access | Times Cited: 147
COVID-19 therapeutics: Challenges and directions for the future
Philip C. Robinson, David Liew, Helen Tanner, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 15
Open Access | Times Cited: 142
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication
Amgad M. Rabie
ACS Omega (2022) Vol. 7, Iss. 3, pp. 2960-2969
Open Access | Times Cited: 97
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review
Fan-shun Zhang, Qing-ze He, Cheng Xue Qin, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 9, pp. 2173-2190
Open Access | Times Cited: 85
Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
Nicola Potere, Marco Giuseppe Del Buono, Roberto Caricchio, et al.
EBioMedicine (2022) Vol. 85, pp. 104299-104299
Open Access | Times Cited: 78
Persistent Oxidative Stress and Inflammasome Activation in CD14highCD16− Monocytes From COVID-19 Patients
Silvia Lucena Lage, Eduardo P. Amaral, Kerry L. Hilligan, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 77
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Ailish Nimmo, Dale Gardiner, Ines Ushiro‐Lumb, et al.
Transplantation (2022) Vol. 106, Iss. 7, pp. 1312-1329
Open Access | Times Cited: 76
Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species
Wafa Ali Eltayb, Mohnad Abdalla, Amgad M. Rabie
ACS Omega (2023) Vol. 8, Iss. 6, pp. 5234-5246
Open Access | Times Cited: 49
The roles of critical pro‐inflammatory cytokines in the drive of cytokine storm during SARS‐CoV‐2 infection
Muhammad Suhaib Qudus, Mingfu Tian, Summan Sirajuddin, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Open Access | Times Cited: 46
Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial
David Conen, Michael Ke Wang, Ekaterine Popova, et al.
The Lancet (2023) Vol. 402, Iss. 10413, pp. 1627-1635
Closed Access | Times Cited: 42
Inflammasome Activation by RNA Respiratory Viruses: Mechanisms, Viral Manipulation, and Therapeutic Insights
Tamara Silva Rodrigues, Dario S. Zamboni
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access | Times Cited: 1
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
Nicole Ezer, Sara Belga, Nick Daneman, et al.
BMJ (2021), pp. e068060-e068060
Open Access | Times Cited: 66
Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients
Chiara Giacomelli, Rebecca Piccarducci, Laura Marchetti, et al.
Biochemical Pharmacology (2021) Vol. 193, pp. 114812-114812
Open Access | Times Cited: 62
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Colchicine for the treatment of COVID-19
Agata Mikołajewska, Anna-Lena Fischer, Vanessa Piechotta, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 58
Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID‐19‐associated thrombopathy
Antoine Caillon, Antonin Trimaille, Julie Favre, et al.
Journal of Thrombosis and Haemostasis (2021) Vol. 20, Iss. 1, pp. 17-31
Open Access | Times Cited: 57
Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies
Amgad M. Rabie, Mohnad Abdalla
ACS Bio & Med Chem Au (2022) Vol. 2, Iss. 6, pp. 565-585
Open Access | Times Cited: 45
Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease
Amgad M. Rabie
ACS Omega (2022) Vol. 7, Iss. 25, pp. 21385-21396
Open Access | Times Cited: 44
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
Aldo Bonaventura, Alessandra Vecchiè, Lorenzo Dagna, et al.
Inflammation Research (2022) Vol. 71, Iss. 3, pp. 293-307
Open Access | Times Cited: 42
Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 42
Social Media and COVID-19—Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics
Natalie Schellack, Morné Strydom, Michael S. Pepper, et al.
Antibiotics (2022) Vol. 11, Iss. 4, pp. 445-445
Open Access | Times Cited: 38
Page 1 - Next Page

Scroll to top